Cartesian Therapeutics, Inc.

RNAC

US8162123025

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
21.03 ^USD	+0.62%		+17.42%	+1.68%

Apr. 23	Leerink Partners Starts Cartesian Therapeutics With Outperform Rating, $39 Price Target	MT
Mar. 14	Cartesian Therapeutics, Inc Receives Notice from Audentes Therapeutics, Inc of Astellas? Termination of the License and Development Agreement	CI

Cartesian Therapeutics, Inc.(NasdaqGM:RNAC) added to NASDAQ Composite Index

November 15, 2023 at 12:00 am EST

Cartesian Therapeutics, Inc Added to NASDAQ Composite Index.

Latest news about Cartesian Therapeutics, Inc.

Leerink Partners Starts Cartesian Therapeutics With Outperform Rating, $39 Price Target	Apr. 23	MT
Cartesian Therapeutics, Inc Receives Notice from Audentes Therapeutics, Inc of Astellas? Termination of the License and Development Agreement	Mar. 14	CI
Cartesian Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Cartesian Therapeutics, Inc. Announces Resignation of Aymeric Sallin as Member of the Board of Director and Member of Compensation Committee	Mar. 05	CI
Cartesian Therapeutics, Inc. Establishes New Corporate Headquarters and mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland	Mar. 05	CI
Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis	Jan. 08	CI
Cartesian Therapeutics, Inc.(NasdaqGM:RNAC) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Cartesian Therapeutics, Inc. Announces Resignation of Scott D. Myers as Member of the Board, Compensation and Nominating and Corporate Governance Committees	Nov. 27	CI
North American Morning Briefing : Stock Futures -2-	Nov. 16	DJ
Cartesian Therapeutics, Inc.(NasdaqGM:RNAC) added to NASDAQ Biotechnology Index	Nov. 15	CI
Cartesian Therapeutics, Inc.(NasdaqGM:RNAC) added to NASDAQ Composite Index	Nov. 15	CI
Cartesian Therapeutics, Inc. announced that it has received $60.249953 million in funding	Nov. 14	CI
Selecta Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Sector Update: Health Care Stocks Gain in Late Afternoon Trading	Nov. 13	MT
Selecta Biosciences Merges With Cartesian Therapeutics	Nov. 13	MT
Transcript : Cartesian Therapeutics, Inc., Selecta Biosciences, Inc. - M&A Call	Nov. 13
Cartesian Therapeutics, Inc. acquired Selecta Biosciences, Inc. for approximately $380 million, in a reverse merger transaction.	Nov. 12	CI
Cartesian Therapeutics, Inc. announced that it expects to receive $60.249876 million in funding	Nov. 12	CI
North American Morning Briefing : Traders Await -2-	Nov. 09	DJ
Selecta Biosciences, Inc. and Swedish Orphan Biovitrum AB (Publ.) Enter into Amendment No. 1 to the License and Development Agreement	23-10-31	CI
Peter Traber, Selecta Biosciences, Inc.?s Chief Medical Officer, Moves to Part-Time Status as Chief Medical Officer, Effective as of November 6, 2023	23-10-31	CI
North American Morning Briefing : Focus Shifts to -2-	23-08-21	DJ
Mizuho Trims Price Target on Selecta Biosciences to $3 From $4, Maintains Buy Rating	23-08-18	MT
Needham Adjusts Price Target on Selecta Biosciences to $4 From $5, Maintains Buy Rating	23-08-18	MT
Transcript : Selecta Biosciences, Inc., Q2 2023 Earnings Call, Aug 17, 2023	23-08-17

Chart Cartesian Therapeutics, Inc.

Duration

Period

More charts

Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

Sector

Biotechnology & Medical Research

Calendar

2024-05-10 - American Society of Gene & Cell Therapy Meeting - Abstract Number: 241

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

21.03 USD

Average target price

56.25 USD

Spread / Average Target

+167.48%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CARTESIAN THERAPEUTICS, INC.	+1.68%	374M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs